CANCER

Cancer

Primary Disciplinary Field(s): Medicine, Oncology, Pathology

1. Core Definition and Pathogenesis

Cancer refers to a complex and heterogeneous group of more than 100 pathological conditions fundamentally characterized by the uncontrolled, abnormal growth of cells. This aberrant proliferation arises from damage to the cellular deoxyribonucleic acid (DNA), leading to mutations in crucial genes that regulate cell division, differentiation, and programmed cell death (apoptosis). Unlike normal cells which follow strict regulatory pathways governing their lifecycle and interaction with surrounding tissues, cancerous cells ignore these intrinsic and extrinsic signals, resulting in sustained proliferative signaling and evasion of growth suppressors. The initiation of cancer is often a multi-step process, requiring the accumulation of several genetic and epigenetic alterations over time, transforming a healthy cell into a malignant one capable of forming a tumor.

The abnormal cellular mass that develops locally is often termed a neoplasm or tumor. Neoplasms are classified primarily based on their potential for malignancy. Benign tumors, while involving abnormal cell growth, typically remain localized, do not invade adjacent tissues, and rarely pose a life-threatening risk unless their size obstructs vital organs. Conversely, malignant tumors—which are synonymous with cancer—possess the critical characteristic of invasiveness. These malignant cells actively breach the basal lamina and surrounding stromal barriers, establishing a capacity to spread beyond their original site. This distinction between benign and malignant proliferation is central to oncology, defining the severity and treatment trajectory of the disease.

The pathogenesis of cancer is deeply rooted in the disruption of the delicate balance between oncogenes and tumor suppressor genes. Oncogenes, when activated by mutation, promote cell growth and division, acting like the accelerator pedal of the cell cycle. Conversely, tumor suppressor genes, such as p53 and Rb, normally act as the brakes, halting division or initiating repair or apoptosis when DNA damage occurs. Cancer progression hinges upon the concurrent activation of oncogenes and the inactivation or loss of function of key tumor suppressor genes. This combined genetic catastrophe leads to genomic instability, increased mutation rates, and the creation of a cellular environment conducive to unlimited replication, a trait famously described as replicative immortality.

2. Etymology and Historical Recognition

The term Cancer derives its name from the Greek physician Hippocrates (c. 460–c. 370 BCE), who described malignant tumors using the word karkinos (carcinos), the Greek term for crab. This terminology was inspired by the appearance of cross-sectioned tumors, particularly those found in the breast, whose prominent veins radiating out into the surrounding tissue resembled the claws of a crab. Later, Roman physician Aulus Cornelius Celsus translated the Greek term into the Latin word cancer, meaning crab, solidifying the nomenclature used today. While the understanding of cancer at the cellular and molecular level is relatively modern, the recognition of these devastating, often fatal, growths dates back thousands of years.

Early civilizations, including the Egyptians, documented conditions recognizable as cancer. The Edwin Smith Papyrus, dating back to 1600 BCE (though possibly based on texts from 2500 BCE), describes cases of breast tumors and notes that there was “no treatment” for the ailment. Through the Middle Ages, the understanding remained largely observational and theoretical, often attributing the disease to imbalances of the four humors (blood, phlegm, yellow bile, and black bile), consistent with Galenic medicine. The concept that cancer was caused by an excess of black bile persisted for centuries, influencing therapeutic attempts which often involved vigorous purging or bloodletting, methods that were ineffective and often harmful.

The true scientific shift occurred during the 17th and 18th centuries with advancements in anatomical pathology and microscopy. Pioneering figures began correlating clinical symptoms with post-mortem findings, moving away from humoral theories toward localized tissue pathology. The 19th century brought the definitive establishment of the cell theory by Schleiden and Schwann, providing the foundational framework necessary to understand cancer as a disease of cellular dysfunction. Rudolf Virchow, often cited as the father of modern pathology, proposed that all cells come from other cells (omnis cellula e cellula), setting the stage for the realization that tumor growth originated from the continuous division of abnormal resident cells. This foundational work paved the way for modern oncology, shifting focus from systemic imbalances to local proliferation and invasion.

3. Key Characteristics and Hallmarks

In 2000, molecular biologists Hanahan and Weinberg synthesized decades of research into a unifying framework known as the “Hallmarks of Cancer,” which describes the functional capabilities acquired by cancer cells during their multistep development. These hallmarks represent fundamental mechanisms of malignant transformation and are critical for understanding diagnosis and targeted therapeutic development. The original six hallmarks included sustaining proliferative signaling, evading growth suppressors, resisting cell death (apoptosis), enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.

However, the biological complexity of malignant disease necessitated an expansion of this framework. Subsequent research identified further acquired capabilities essential for full malignancy. These expanded hallmarks include the ability to deregulate cellular energetics—often shifting metabolism toward aerobic glycolysis (the Warburg effect)—and avoiding immune destruction. The immune system, specifically T-cells and Natural Killer (NK) cells, is normally capable of identifying and eliminating aberrant cells, but cancer cells develop sophisticated mechanisms to modulate the tumor microenvironment, suppress immune responses, and escape immunosurveillance, a critical step in advanced disease progression.

Furthermore, two underlying enabling characteristics are now recognized as foundational to the acquisition of all other hallmarks: genomic instability and mutation, and tumor-promoting inflammation. Genomic instability ensures the high mutation rate necessary to acquire all required hallmarks in a biologically relevant timeframe. Tumor-promoting inflammation, often mediated by immune cells recruited to the tumor site (such as macrophages), releases growth factors, pro-angiogenic signals, and enzymes that facilitate invasion and metastasis, essentially co-opting the body’s repair mechanisms to fuel tumor growth and spread.

• Sustained Proliferative Signaling: Cancer cells produce their own growth factors or maintain signaling pathways constantly “on,” ensuring continuous, unregulated growth.
• Evasion of Growth Suppressors: Inactivation of key regulatory proteins (like p53 or Rb) that normally pause the cell cycle in response to stress or damage.
• Resisting Cell Death (Apoptosis): Altering internal signaling pathways to ignore the signals for programmed cell death, ensuring cell survival even under highly stressful conditions.
• Inducing Angiogenesis: Stimulating the formation of new blood vessels from pre-existing vasculature to supply the growing tumor mass with oxygen and nutrients (neovascularization).
• Genomic Instability: A defect in DNA repair mechanisms leading to a dramatically increased rate of mutations, accelerating the acquisition of malignant traits.

4. Classification and Nomenclature

Cancers are primarily classified based on the cell type or tissue of origin. This classification is vital for diagnosis, prognosis, and determining appropriate treatment protocols. The four major categories encompass the vast majority of human malignancies. The most common type is the Carcinoma, originating in the epithelial cells that line the internal and external surfaces of the body, such as the skin, breast, lungs, digestive tract, and glandular organs (e.g., adenocarcinomas). The source content notes: “A carcinoma is a cancer involving the epithelial cells of organs such as the skin, breast, uterus, and stomach.” Carcinomas account for roughly 90% of all human cancers.

The second major class is Sarcoma, which arises from connective tissues, including bone (osteosarcoma), cartilage, fat (liposarcoma), muscle, and blood vessels. These are generally rarer than carcinomas but can be highly aggressive. The third class includes cancers of the hematopoietic (blood-forming) and lymphoid tissues, encompassing Leukemia (cancers originating in the bone marrow, often leading to excessive production of abnormal white blood cells) and Lymphoma (cancers arising from the lymphatic system, specifically lymphocytes). These cancers often present as systemic diseases rather than solid tumors.

The fourth major category is Glioma and other nervous system cancers, which originate in the tissues of the central nervous system (CNS). These include tumors derived from glial cells (such as astrocytes and oligodendrocytes) and neurons. Beyond these four primary groups, cancers are further classified by histology (microscopic appearance), grade (how abnormal the cells look and how quickly they are multiplying), and stage (the size of the tumor and the extent of spread throughout the body). The precise nomenclature, often incorporating suffixes like -oma (indicating a tumor) and prefixes referencing the tissue type (e.g., fibro-, adeno-, osteo-), provides oncologists with critical information regarding the cancer’s biological identity.

5. Metastasis and Invasion

The most lethal characteristic of malignant disease is its capacity to spread to distant organs from the primary tumor site, a process known as metastasis. Metastasis is responsible for approximately 90% of cancer-related deaths. The process is complex, involving the detachment of cancer cells from the primary tumor, local invasion of the surrounding stroma, entry into the bloodstream or lymphatic vessels (intravasation), survival within the circulation, arrest in a distant capillary bed, extravasation into the new tissue environment, and finally, colonization and proliferation in the secondary site.

During the initial phase of invasion, cancer cells undergo crucial phenotypic changes, often involving the Epithelial-Mesenchymal Transition (EMT). EMT allows stationary epithelial cells to lose cell-to-cell adhesion and gain migratory and invasive properties typical of mesenchymal cells. These cells then secrete lytic enzymes, such as matrix metalloproteinases (MMPs), which degrade the extracellular matrix (ECM) and basement membrane, paving the way for their escape into the circulation. The ability of a cancer cell to survive the harsh environment of the bloodstream, evade immune clearance, and establish a viable secondary tumor dictates whether the metastatic cascade will be successful.

The pattern of metastasis is often predictable, though not absolute, depending on the primary site and the anatomical route of drainage. For example, cancers originating in the digestive tract often metastasize first to the liver due to portal circulation, while breast and lung cancers frequently spread to bone, brain, and lung tissue. The concept of the “seed and soil” hypothesis, originally proposed by Stephen Paget in 1889, remains relevant, suggesting that metastasis is not merely a random mechanical process but requires a specific interaction between the circulating tumor cell (the seed) and a favorable microenvironment in the distant organ (the soil) to successfully colonize and grow.

6. Etiology and Risk Factors

Cancer is fundamentally a genetic disease, but only a small percentage (5–10%) is due to inherited mutations (e.g., BRCA1/BRCA2 in breast cancer). The overwhelming majority (90–95%) is attributable to acquired somatic mutations resulting from environmental exposures and lifestyle choices. Identifying and mitigating these risk factors forms the core of primary cancer prevention strategies. Lifestyle factors include tobacco use, which is the single largest preventable cause of cancer worldwide, contributing to malignancies in the lung, larynx, esophagus, bladder, and pancreas. Poor diet, obesity, and physical inactivity are also major contributing factors, linked strongly to cancers of the colon, breast, and endometrium.

Environmental and occupational exposures represent another significant etiological category. Prolonged exposure to carcinogens—substances capable of causing cancer—such as asbestos, radon gas, benzene, and heavy metals, can induce DNA damage leading to malignant transformation. Radiation exposure, both from ultraviolet (UV) light (leading to skin cancer) and ionizing radiation (e.g., medical imaging or occupational exposure), is a well-established cause. Furthermore, chronic infections are responsible for a substantial global cancer burden, particularly in developing nations. Viruses such as Human Papillomavirus (HPV, linked to cervical and head/neck cancers), Hepatitis B and C viruses (HBV/HCV, linked to liver cancer), and Epstein-Barr Virus (EBV, linked to certain lymphomas) are categorized as oncogenic pathogens because they induce chronic inflammation and genetic instability necessary for carcinogenesis.

Age is perhaps the most prominent non-modifiable risk factor for most common cancers. Cancer incidence rises dramatically with age because the process requires the accumulation of multiple somatic mutations, a process spanning decades. Older individuals have had more time for exposure to environmental carcinogens and have accumulated more replication errors. Furthermore, the efficiency of DNA repair mechanisms and immune surveillance tends to decline with age, making the body less capable of correcting genetic damage or eliminating nascent malignant cells, thereby accelerating the carcinogenic process in the elderly population.

7. Clinical Significance and Treatment Modalities

The clinical significance of cancer is immense, representing a leading cause of morbidity and mortality globally. Effective management requires a multidisciplinary approach tailored to the specific type, stage, and molecular profile of the tumor, often involving a combination of therapies administered by surgical oncologists, radiation oncologists, and medical oncologists. Traditional treatment pillars include surgery, which aims to physically remove the primary tumor and any involved regional lymph nodes; radiation therapy, which uses high-energy rays to kill cancer cells and shrink tumors; and chemotherapy, which employs systemic drugs to kill rapidly dividing cells throughout the body.

In the 21st century, oncology has been revolutionized by the development of targeted therapies and immunotherapies, shifting treatment away from non-specific cytotoxic agents. Targeted therapies are designed to interfere with specific molecular pathways essential for cancer growth, such as blocking growth factor receptors (e.g., EGFR inhibitors) or inhibiting overactive signaling proteins (e.g., kinase inhibitors). These drugs are significantly less toxic than traditional chemotherapy because they selectively attack cancer cells based on their unique genetic vulnerabilities. They require precise molecular profiling of the tumor to identify actionable mutations.

Immunotherapy represents one of the most significant breakthroughs, capitalizing on the body’s own immune system to fight cancer. Strategies include the use of checkpoint inhibitors (such as PD-1/PD-L1 blockers), which essentially release the “brakes” on T-cells, allowing them to recognize and attack tumor cells previously shielded by immune evasion mechanisms. Another revolutionary technique is Chimeric Antigen Receptor (CAR) T-cell therapy, where a patient’s T-cells are genetically engineered in a laboratory to specifically target antigens on their cancer cells, demonstrating remarkable efficacy against certain hematologic malignancies. The continued advancement in precision medicine promises increasingly personalized and effective approaches, transforming many previously fatal diagnoses into manageable chronic conditions.

8. Further Reading

• National Cancer Institute (NCI): What is Cancer?
• Wikipedia: Hallmarks of Cancer (Hanahan and Weinberg)
• World Health Organization (WHO): Cancer Overview
• Wikipedia: Metastasis